FDA Exempts Eight More Device Classes From Premarket Notification Requirements

August 21, 2015

Last month FDA published a guidance (titled “Intent to Exempt Certain Unclassified, Class II, and Class I Reserved Medical Devices from Premarket Notification Requirements”) announcing that they would not be enforcing compliance with 510(k) requirements for certain classes of medical devices, and with that announcement they released a list of the 120 exempt classes (full list of exempt device classes here). This meant any devices falling into one of the 120 exempt classes would no longer have to comply with FDA’s premarket notification and review requirements, making it significantly easier to get device(s) on the market faster.

Last week, FDA updated this guidance adding eight additional classes that will no longer be required to comply with the Agency’s premarket notification and review requirements. The additional classes include the following:

Cardiovascular Devices:

  • DTL – Adaptor, Stopcock, Manifold, Fitting, Cardiopulmonary Bypass

Gastroenterology Devices:

  • OCY – Endoscopic Guidewire, Gastroenterology-urology
  • KOE – Dilator, Urethral

General & Plastic Surgical Devices:

  • FTA – Light, Surgical, Accessories

Neurological Devices:

  • GZM – Analyzer, Rigidity
  • GZO – Device, Galavanic Skin Response Measurement
  • HCJ – Device, Skin Potential Measurement

Ophthalmic Devices:

  • HLJ – Ophthalmoscope, Battery Powered

Not sure if your device falls into one of the exempt categories or not? We can help figure it out and achieve a successful outcome with FDA during the entire process of getting your medical device on the market. For more information on our services and how we can help you, please contact us.

Medical Devices Agency Alerts

February 28, 2019

Draft Guidance: Requesting Nonbinding Feedback After an FDA Inspection of Your Medical Device Establishment

On Tuesday, February 19th, FDA published a draft guidance for medical device makers which identifies a process for companies to request nonbinding feedback on certain FDA Form 483 deficiencies noted...

Read the Full Article
Agency Alerts General Regulatory

August 28, 2015

FDA Extends Comment Period For Its “Request for Quality Metrics” Draft Guidance

Last month, FDA published a draft guidance titled “Request for Quality Metrics,” which outlined the ways in which it intends to collect and use quality metrics. The guidance states that the data will...

Read the Full Article
Agency Alerts General Regulatory

June 16, 2017

FDA to Host Public Workshop to Discuss the Impact of Abuse Deterrent Opioids

On Wednesday, June 14th, the FDA announced plans to host a public workshop regarding the impact of opioid formulations with abuse deterrent properties.  The workshop, entitled “Data and Methods for...

Read the Full Article